Adaptive Radiotherapy in Locally Advanced Head and Neck Cancers: Impact on Target Volume Shrinkage and Organ at Risk and its Clinical Outcome
Sukhveer Tanwar, Shikha Dhal, Sumit Goyal
Adaptive, Cancer, Tumor volume
Citation Information :
Tanwar S, Dhal S, Goyal S. Adaptive Radiotherapy in Locally Advanced Head and Neck Cancers: Impact on Target Volume Shrinkage and Organ at Risk and its Clinical Outcome. J Mahatma Gandhi Univ Med Sci Tech 2021; 6 (3):79-81.
Positional uncertainties due to tumor shrinkage and weight loss, leads to decrease therapeutic ratio due to higher treatment toxicity and decreased local control rates. Adaptive Radiotherapy refers to changing treatment plan during the treatment sessions to account for this decreased therapeutic ratio. Total of 50 patients were treated with image-guided radiotherapy for locally advanced head and neck cancers. Replan was done at 17th fraction. The cross-comparison of dosimetric analysis of GTV 100 and PTV 95 was statistically significant. Mean volume reduction rate in ipsilateral parotid and contralateral parotid was in our study mean shrinkage in volume of right parotid 13–10.4 cc, left parotid 14–10.5 cc, respectively. Patients who had TVRR ≥20% at interim replan done after 17 fractions at 4th week had complete response at 6 months after treatment while in patients with TVRR <20%, 42% had complete response at 6 months. Out of 50 patients enrolled in the study 32 patients (64%) had complete response on clinical evaluation and follow-up CT scan.
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492
Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin Oncol 1994;21(3):281–288.
Pfister DG, Foote RL, Gilbert J, et al. NCCN Guidelines Index Table of Contents Discussion. 2018;227.
Wu Q, Manning M, Schmidt-Ullrich R, et al. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000;46(1):195–205. DOI: 10.1016/s0360-3016(99)00304-1
Chao KC, Majhail N, Huang C, et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 2001;61(3):275–280. DOI: 10.1016/s0167-8140(01)00449-2
Dogan N, King S, Emami B, et al. Assessment of different IMRT boost delivery methods on target coverage and normal-tissue sparing. Int J Radiat Oncol Biol Phys 2003;57(5):1480–1491. DOI: 10.1016/s0360-3016(03)01569-4
Li Y, Taylor JM, Ten Haken RK, et al. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2007;67(3):660–669. DOI: 10.1016/j.ijrobp.2006.09.021
Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66(4):981–991. DOI: 10.1016/j.ijrobp.2006.06.013
Mendenhall WM, Mancuso AA, Morris CG, et al. Influence of tumour volume on the probability of local control after radiotherapy for squamous cell carcinoma of the head and neck. JHK Coll Radiol 2003;6:119–125.
Strongin A, Yovino S, Taylor R, et al. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;82(5):1823–1830. DOI: 10.1016/j.ijrobp.2010.10.053
Lok BH, Setton J, Caria N, et al. Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys 2012;82(5):1851–1857. DOI: 10.1016/j.ijrobp.2011.03.029
Been MJ, Watkins J, Manz RM, et al. Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapy. Laryngoscope 2008;118(8):1377–1382. DOI: 10.1097/MLG.0b013e318172c82c
Yang S-N, Liao C-Y, Chen S-W, et al. Int J Radiat Oncol Biol PhysClinical implications of the tumor volume reduction rate in head-and-neck cancer during definitive intensity-modulated radiotherapy for organ preservation. 2011;79(4):1096–1103. DOI: 10.1016/j.ijrobp.2009.12.055
Lee H, Ahn YC, Oh D, et al. Tumor volume reduction rate measured during adaptive definitive radiation therapy as a potential prognosticator of locoregional control in patients with oropharyngeal cancer. Head Neck 2014;36(4):499–504. DOI: 10.1002/hed.23328
Péus D, Newcomb N, Hofer S. Appraisal of the Karnofsky performance status and proposal of a simple algorithmic system for its evaluation. BMC Med Inform Decis Mak 2013;13(1):72.Available from: http://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/1472-6947-13-72 DOI: 10.1186/1472-6947-13-72
ICRU-50. ICRU Report 50. 1993;
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–1346. DOI: 10.1016/0360-3016(95)00060-C
O'Daniel JC, Garden AS, Schwartz DL, et al. Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get? Int J Radiat Oncol Biol Phys 2007;69(4):1290–1296. DOI: 10.1016/j.ijrobp.2007.07.2345
Dijkema T, Raaijmakers CP, Ten Haken RK et al. Parotid gland function after radiotherapy: the combined Michigan and Utrecht experience. Int J Radiat Oncol Biol Phys 2010;78(2):449–453. DOI: 10.1016/j.ijrobp.2009.07.1708